Page 179 - Drug Class Review
P. 179
Drug Effectiveness Review Project
Drugs Authors: Rogers et al. 43 Eisai Inc, Teaneck NJ and Eisai Co Ltd, Tokyo Japan To examine the efficacy and safety of DON in treatment of mild to moderately severe AD Setting: Multi-center (23 clinical centers) placebo donepezil 10 mg donepezil 5 mg N/A 10 mg/d 5 mg/d 12 weeks 12 weeks 12 weeks 153 158 157 >50 yrs old; diagnosis of probable AD consistent with NINCDS and DSM-IV criteria; mild to moderately severe disease based on MMSE scores of 10-26; CDR scores of 1 or 2 Major medical illness – diabetes, COPD, asthma, hematologic or oncologic disorders; vitamin
Alzheimer Year: 1998 Country: US Study design: RCT Sample size: 468
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
